Zhitong Finance App News, China Resources Shuanghe (600062.SH) issued an announcement. Recently, the company, its wholly-owned subsidiary Xi'an Jingxi Shuanghe Pharmaceutical Co., Ltd., and the holding subsidiary China Resources Shuanghexiang Chinese Pharmaceutical (Hunan) Co., Ltd. each received the “Drug Registration Certificate” for injectable esaconazole sulfate, sorbitol mannitol rinse, and bryprazole tablets issued by the State Drug Administration.

According to reports, injectable isaconazole sulfate is suitable for the treatment of the following infections in adults and children aged 1 year and above: invasive aspergillosis and invasive furuncles. Sorbitol mannitol rinse is suitable for intraoperative flushing during transurethral prostatectomy and other urological procedures. Briprazole tablets are used to treat schizophrenia in adults. This time, the injectable isaconazole sulfate, sorbitol mannitol rinse agent, and briprazole tablets obtained the “Drug Registration Certificate”, which will further enrich the company's product line, help enhance the market competitiveness of the company's products, and accumulate valuable experience for subsequent development of other products.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.